

Introduction:

AAD and GRAPPA Psoriasis Assessment Tools
for MIPS Quality Measure 410

MIPS: Merit-Based Incentive Payment System

- If you decide to participate in the Merit-based Incentive Payment System (MIPS), you will earn a performance-based payment adjustment to your Medicare payment.
- Your practice or institution will need to select and meet the criteria for certain performance measures in order to earn this payment adjustment.

MEASURE 410:

Psoriasis Quality Measure:

Clinical Response to Oral Systemic or
Biologic Medications

Measure 410:

Psoriasis: Clinical Response to Oral Systemic or Biologic Medications

- To satisfy this measure, a patient must achieve ONE of the following:
 - Physician Global Assessment (PGA; 6-point scale) ≤ 2 (clear to mild skin disease)
 - Body Surface Area (BSA) $< 3\%$ (mild disease)
 - Psoriasis Area and Severity Index (PASI) < 3 (no or minimal disease)
 - Dermatology Life Quality Index (DLQI) ≤ 5 (no effect or small effect on patient's quality of life)

Rationale?

A significant proportion of psoriasis patients who are receiving treatment remain **unsatisfied** with their therapies due to various reasons including lack of, or loss of efficacy, side effects, and inconvenience, among others.


Treatment dissatisfaction also contributes to patients discontinuing therapy.

What does it measure?


This measure evaluates the **proportion** of psoriasis patients receiving **oral systemic or biologic therapy** who meet **minimal physician or patient-reported disease activity levels**.

This proportion is your **Performance Rate** for Psoriasis Quality Measure 410.

PERFORMANCE RATE




and




DENOMINATOR

NUMERATOR

PASI < 3 or BSA < 3% or PGA ≤ 2 or DLQI ≤ 5



and



DENOMINATOR


What if the patient doesn't meet criteria?

The Denominator Exception:


- Denominator exceptions are those conditions that should **remove** a patient, procedure or unit of measurement from the denominator only if the numerator criteria are not met.

NUMERATOR

PASI < 3 or BSA < 3 or PGA ≤ 2 or DLQI ≤ 5



and



minus

- treated < 6 months
- declined therapy change
- documented contraindications
 - adverse effects
 - lack of efficacy with all other therapy options

DENOMINATOR

EXCEPTIONS

The AAD and GRAPPA have partnered to provide four short educational videos on how to perform the candidate psoriasis assessments:

- BSA
- PGA
- DLQI
- PASI

These videos and more information on the Psoriasis Quality Measure, such as how to calculate the performance rate, can be found on the AAD Website at www.aad.org/410

We hope that you find this information useful.